Sarissa Investment in Amarin
Hedge Fund Presentation Collection
In 2023, Sarissa Capital Management increased its stake in Amarin Corporation and gained board representation to influence the company’s strategic direction and enhance shareholder value.
| Fund | Sarissa |
| Target | Amarin |
| Sector | Healthcare |
| Year | 2023 |
Sarissa Capital invested in Amarin in 2023 and made public a presentation for it. If you are interested to learn about how hedge funds write presentations, here is one for you to learn from.
The Sarissa Capital Deck
This deck is in the public domain (Nothing privately shared is ever distributed on this site).
About the Amarin deal
In 2023, Sarissa Capital Management, led by Alex Denner, increased its investment in Amarin Corporation, a pharmaceutical company known for its fish oil-derived drug, Vascepa. Sarissa, which had already been a significant shareholder, intensified its involvement by securing seats on Amarin’s board of directors. This move was part of Sarissa’s strategy to influence the company’s direction and improve its operational and financial performance. The increased investment and board presence underscored Sarissa’s confidence in Amarin’s potential and its commitment to driving strategic changes to enhance shareholder value.
One sentence
About Sarissa Capital
Sarissa Capital Management is an activist hedge fund founded in 2013 by Alex Denner, a former portfolio manager at Carl Icahn’s Icahn Enterprises. The firm focuses on the healthcare sector, investing in companies with the aim of driving strategic changes to unlock shareholder value. Sarissa Capital is known for taking significant stakes in companies and pushing for changes in corporate governance, strategy, and operations to enhance performance and returns.
About Amarin
Amarin Corporation is a biopharmaceutical company based in Dublin, Ireland, and Bridgewater, New Jersey, specializing in developing and commercializing therapeutic products for cardiovascular health. The company is best known for its flagship product, Vascepa (icosapent ethyl), an omega-3 fatty acid derivative used to reduce cardiovascular risk in patients with elevated triglycerides. Amarin focuses on addressing unmet medical needs in cardiovascular disease and aims to improve patient outcomes through its innovative therapies.
Want to see more?
Head here to see the rest of the collection:
Comments (0)
There are no comments yet :(